The global cardiac markers market is expected to grow at a significant CAGR during the forecast period (2022-2028). When the heart is strained or its muscles are injured, cardiac markers or cardiac biomarkers are released into the bloodstream. These markers include cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin, among other enzymes, hormones, and proteins. These markers can be measured and tested to aid in the diagnosis of heart diseases such as myocardial ischemia and acute coronary syndrome (ACS). Electrocardiograms (ECGs) and clinical history are currently employed in diagnostic systems to determine the risk of certain disorders. These methods are insufficient and can lead to misdiagnosis or treatment delays. Cardiac marker testing is gaining popularity since it is more accurate and can detect problems in the early stages of presentation. 

Lifestyle diseases including hypertension, obesity, dyslipidemia, and diabetes, all of which are substantial risk factors for CVD, are also on the rise, which in turn is contributing to the growth of the global cardiac marker market. It is estimated that 93 million adults in the US are obese or clinically obese, with a BMI of 30 or more. Obesity affects about 650 million people globally. As per World Health Organization (WHO), CVDs claimed the lives of 17.9 million people globally in 2019, accounting for 32% of all mortalities. Heart attacks and strokes were responsible for 85% of these deaths. Low- and middle-income nations account for about three-quarters of CVD mortality. CVDs were responsible for 38% of the 17 million premature mortalities (before the age of 70) caused by noncommunicable diseases in 2019. Furthermore, various private and public organisations are engaging in R&D operations in the field of cardiac biomarkers to create innovative technology. For instance, blood tests for high-sensitivity cardiac troponin have been shown to identify patients at higher risk of a second heart attack.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Product 
• By Application 
• By Testing Type 

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  F. Hoffmann-La Roche Ltd., Abbott Laboratories, and bioMérieux SA, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cardiac Markers Market Report by Segment

By Product 

• Troponins (T and I) 
• Myocardial Muscle Creatine Kinase (CK-MB)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP 
• Ischemia Modified Albumin (IMA) 
• Others

By Application

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others 

By End-User

• Laboratory Testing
• Point-of-Care Testing

Global Cardiac Markers Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa